GSK announced it has received approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research expanding the indication for FLUARIX QUADRIVALENT (Influenza Vaccine) to include use in persons 6 months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older. With this approval, providers will be able to use the same dose of FLUARIX QUADRIVALENT (15 ug of hemagglutinin per virus strain in 0.5 mL) to cover all eligible persons from 6 months of age and up. The supplemental Biologics License Application was based on a Phase III pivotal study of the efficacy of FLUARIX QUADRIVALENT in children 6 months through 35 months of age and on two supportive studies.